Langerhans cell histiocytosis: 2026 so far

Evidence broadened from refractory control to CNS-specific cohorts.

In January 2026 to September 2026, a large real-world pediatric report showed very high short-term response rates to off-label MAPK inhibitors (targeted drugs aimed at the MAPK pathway) in refractory LCH. The same cohort also clarified limits. Responses were much lower for lung destruction. In that cohort, there were no responses for neurodegeneration or diabetes insipidus (a hormone-related condition that causes excessive thirst and urination). Reactivation after stopping therapy was common among those who discontinued. Later reports in the months covered described separate real-world cohorts. One focused on neurodegenerative LCH (LCH-related brain changes that can worsen over time) and reported symptom and brain MRI (magnetic resonance imaging) improvement in many children treated with MAPK inhibitors. Other reports described clinical and imaging improvement in mixed adult histiocytosis cohorts treated with trametinib (sometimes with dabrafenib). Side effects were frequent, and some people stopped treatment. Across reports, side effects were common, often involving skin and the GI tract (gastrointestinal tract, meaning stomach and intestines). Some patients needed dose reductions or discontinued treatment, which can affect what benefits are realistic for a given organ problem and how long control may last after stopping.

Research covered in: February 2026, March 2026, May 2026, June 2026, July 2026, August 2026

More salvage approaches reported, including phase II clofarabine.

So far in 2026, several small pediatric studies and case series described disease control while using different relapsed/refractory approaches. These included LENDEX (lenalidomide plus dexamethasone), trametinib or dabrafenib/trametinib in selected mutation contexts, and local radiofrequency ablation (using heat to destroy tissue) for painful bone lesions. A phase II study (a mid-stage trial testing whether a treatment works and is safe) that was prospective and multicenter reported a high early response to clofarabine in recurrent/refractory pediatric LCH. Most participants had grade 3+ toxicities (severe side effects), showing a clear benefit-harm tradeoff. Small series also noted that staying controlled on treatment may not match what happens after stopping. Relapses after trametinib withdrawal were reported, which can influence how families and care teams think about the risks of stopping versus continuing.

Research covered in: March 2026, May 2026, July 2026

Sharper risk separation for liver disease; new bone-support data.

In the months covered, one pediatric multisystem LCH report with liver involvement separated children into enlarged liver with preserved function versus liver dysfunction (the liver not working normally). Survival was markedly worse in the liver dysfunction group. In that study, lack of improvement by week 6 was the strongest warning sign. Supportive care evidence also added a few short-term signals. A small pediatric series linked zoledronate with rapid pain improvement and radiographic improvement (changes seen on imaging) in bone LCH. An uncontrolled adult study found that vitamin D supplementation was followed by higher vitamin D levels, lower CTX (a blood marker of bone breakdown), and some pain and daily-function quality-of-life improvements over 3 months. Case reports in January 2026 to September 2026 also illustrated serious complications. These included severe Pneumocystis pneumonia (a serious fungal lung infection) with respiratory failure during pediatric therapy requiring ECMO (a heart-lung machine that supports oxygenation), and multiple severe infections in a premature infant during systemic chemotherapy. Together, these reports reinforce that organ-specific risks and supportive care needs can be measurable even over short time windows, but much of the evidence is still observational or based on individual cases.

Research covered in: May 2026, June 2026, July 2026, August 2026, September 2026

Large cohort clarified who often stays stable without treatment.

A large multi-center report of biopsy-proven unifocal bone LCH (single-system, single-site disease confirmed by tissue sampling) without CNS-risk bones described that many children did well for several years with watchful waiting. When events occurred, they were usually within 12 months. They often involved new lesions rather than growth of the original lesion. The same report found better event-free survival in children staged with PET-CT (a scan combining metabolic imaging and CT pictures) versus conventional imaging. This suggests that more sensitive staging may better identify truly single-site disease, though this was not a randomized comparison. Other pediatric cohorts in the months covered continued to report high overall survival, along with relapse or reactivation in some subsets. In practice, this supports observation-only management for carefully defined low-risk bone presentations, while also highlighting the first year as an important window for follow-up in that group.

Research covered in: January 2026, April 2026, May 2026

More PET/CT staging data; early neurodegeneration markers explored.

In reports from January to September 2026, PET-based whole-body imaging (scans that highlight metabolically active disease) repeatedly appeared as a way to find additional disease sites. It sometimes changed classification compared with CT/MRI. One small study in 15 people with systemic histiocytosis, including LCH, compared PET/MRI with PET/CT and found they were mostly concordant, with PET/CT better for evaluating lung lesions. Several studies also linked baseline PET/CT activity measures and/or risk-organ involvement with later progression or relapse in pediatric cohorts. Other work explored blood or CSF markers (cerebrospinal fluid, the fluid around the brain and spinal cord). NFL (neurofilament light, a protein that can rise with nerve damage) was higher in children with neurodegenerative LCH than in those without. However, blood NFL at initial diagnosis did not predict later neurodegeneration. A separate early dataset reported CSF IL-1RT2 distinguishing neurodegenerative LCH from other LCH groups. Exploratory tools in the months covered also included blood-based BRAF V600E tracking (HistioTrak) in a small trametinib-treated cohort, and machine-learning models (computer models that learn patterns from data) using pituitary MRI to help distinguish sellar-region diagnoses. Overall, the direction is toward more tailored combinations of imaging and biomarkers, but most of these tools are still early and not yet validated for routine decisions.

Research covered in: February 2026, April 2026, May 2026, June 2026, July 2026, September 2026